^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR-A1912

    i
    Other names: SHR-A1912, SHRA1912, SHR A1912
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Topoisomerase I inhibitor, CD79b-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    9ms
    SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=924, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1 trial • Metastases
    |
    capecitabine • oxaliplatin • SHR-A1904 • SHR-A1912
    12ms
    A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma (clinicaltrials.gov)
    P1/2, N=132, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SHR-A1912
    1year
    A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas (clinicaltrials.gov)
    P1, N=170, Enrolling by invitation, Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting --> Enrolling by invitation | Trial primary completion date: Dec 2023 --> Mar 2024
    Enrollment status • Trial primary completion date
    |
    SHR-A1912
    1year
    A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma (clinicaltrials.gov)
    P1/2, N=132, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    SHR-A1912
    over1year
    A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas (clinicaltrials.gov)
    P1, N=170, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | N=123 --> 170 | Trial completion date: Jun 2024 --> Mar 2025
    Enrollment change • Trial completion date
    |
    SHR-A1912